Delivery Order SPE2DB22D9367-SPE2DB25FSZ53
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc. for the supply of Alecensa 150 mg capsules (240-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge location with an ultimate completion date of September 10, 2025. This award carries no set-aside designation, allowing the vendor to compete on...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-unit quantity) with a ceiling value of $25,564.66. This firm fixed-price delivery order, awarded on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $49,897.20 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Alecensa 150 mg capsules. This order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products to support the medical...
- The Defense Logistics Agency awarded a $12.78K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240 count). The contract, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a direct procurement for pharmaceutical products supporting Department of Defense healthcare needs. The contract...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $49,897.20 contract is for the delivery of Alecensa 150 mg capsules. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 4,568,462,391 units of the prescription drug Alecensa (150 mg capsules) with a ceiling value of $12,782.32. The contract has an ultimate completion date of June 25, 2025. DMS Pharmaceutical Group Inc. is an established federal contractor, holding...
- This is a $12,782.32 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Alecensa 150 mg capsules and has an ultimate completion date of June 18, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $51,129.28 on July 18, 2025, for Alecensa 150 mg capsules (240-count units) under a Defense Logistics Agency contract. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a single transaction within DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, awarded on July 21, 2025, carries a ceiling value of $12,782.32 and is scheduled for ultimate completion by August 11, 2025. The contract was awarded without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSZ53Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc. for the supply of Alecensa 150 mg capsules (240 count units). The contract was awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, and carries a firm fixed-price structure with no set-aside designation. The delivery location is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters operations. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, executed this delivery order under its larger Indefinite Delivery Contract (IDC) with the DLA valued at $499.999 billion and valid through November 2026. The company serves as a critical supplier in the federal pharmaceutical supply chain, distributing a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. Alecensa (alectinib), an oncology medication, falls within the company's demonstrated portfolio of specialty pharmaceutical products supporting military health systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 8/29/25 |